Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz
Gewählte Publikation:
SHR Neuro Krebs Kardio Lipid Stoffw Microb
Michl, U; Molfenter, F; Graefen, M; Tennstedt, P; Ahyai, S; Beyer, B; Budäus, L; Haese, A; Heinzer, H; Oh, SJ; Salomon, G; Schlomm, T; Steuber, T; Thederan, I; Huland, H; Tilki, D.
Use of phosphodiesterase type 5 inhibitors may adversely impact biochemical recurrence after radical prostatectomy.
J Urol. 2015; 193(2):479-83
Doi: 10.1016/j.juro.2014.08.111
Web of Science
PubMed
FullText
FullText_MUG
- Co-Autor*innen der Med Uni Graz
- Ahyai Sascha
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- PURPOSE: Experimental evidence suggests that phosphodiesterase type 5 inhibitors may suppress tumor growth, postpone metastasis and prolong survival, but clinical data are lacking. We studied the effect of phosphodiesterase type 5 inhibitors on biochemical recurrence after radical prostatectomy for prostate cancer. MATERIALS AND METHODS: The study was comprised of 4,752 consecutive patients with localized prostate cancer treated with bilateral nerve sparing radical prostatectomy between January 2000 and December 2010. Of these patients 1,110 (23.4%) received phosphodiesterase type 5 inhibitors postoperatively while 3,642 (76.6%) did not. The risk of biochemical recurrence was compared between the phosphodiesterase type 5 inhibitor group and the nonphosphodiesterase type 5 inhibitor group. Cox multivariate proportional hazard models and confidence intervals were used to estimate the hazard ratio of biochemical recurrence associated with phosphodiesterase type 5 inhibitor use. Propensity score matched analysis was performed. RESULTS: Median followup was 60.3 months (IQR 36.7-84.5). Five-year biochemical recurrence-free survival estimates in the phosphodiesterase type 5 inhibitor vs nonphosphodiesterase type 5 inhibitor groups were 84.7% (95% CI 82.1-87.0) and 89.2% (95% CI 88.1-90.3), respectively (p=0.0006). Multivariate regression analysis showed that phosphodiesterase type 5 inhibitor use was an independent risk factor for biochemical recurrence (HR 1.38, 95% CI 1.11-1.70, p=0.0035) and this was also true after propensity score matching. CONCLUSIONS: Contrary to experimental data, the use of phosphodiesterase type 5 inhibitors after radical prostatectomy may adversely impact biochemical recurrence. Further studies are needed to validate our results.
- Find related publications in this database (using NLM MeSH Indexing)
- Aged - administration & dosage
- Follow-Up Studies - administration & dosage
- Humans - administration & dosage
- Male - administration & dosage
- Middle Aged - administration & dosage
- Neoplasm Recurrence, Local - chemically induced
- Phosphodiesterase 5 Inhibitors - adverse effects
- Prostatectomy - administration & dosage
- Prostatic Neoplasms - chemically induced, surgery
- Retrospective Studies - administration & dosage
- Find related publications in this database (Keywords)
- prostatic neoplasms
- prostatectomy
- phosphodiesterase 5 inhibitors
- recurrence